Sharon Shacham
2017
In 2017, Sharon Shacham earned a total compensation of $2.5M as President and Chief Scientific Officer at Karyopharm Therapeutics, a 83% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $171,856 |
|---|---|
| Option Awards | $1,857,650 |
| Salary | $435,000 |
| Other | $11,460 |
| Total | $2,475,966 |
Shacham received $1.9M in option awards, accounting for 75% of the total pay in 2017.
Shacham also received $171.9K in non-equity incentive plan, $435K in salary and $11.5K in other compensation.
Rankings
In 2017, Sharon Shacham's compensation ranked 4,471st out of 14,666 executives tracked by ExecPay. In other words, Shacham earned more than 69.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,471 out of 14,666 | 70th |
Division Manufacturing | 1,573 out of 5,768 | 73rd |
Major group Chemicals And Allied Products | 453 out of 2,074 | 78th |
Industry group Drugs | 348 out of 1,730 | 80th |
Industry Pharmaceutical Preparations | 275 out of 1,329 | 79th |
Source: SEC filing on April 27, 2018.
Shacham's colleagues
We found two more compensation records of executives who worked with Sharon Shacham at Karyopharm Therapeutics in 2017.
News
Karyopharm Therapeutics CEO Richard Paulson receives $8.4M in 2021
April 8, 2022
Karyopharm Therapeutics CEO Michael Kauffman's 2020 pay jumps 22% to $3.9M
April 7, 2021
Karyopharm Therapeutics CEO Michael Kauffman's 2019 pay jumps 42% to $3.2M
April 9, 2020
Karyopharm Therapeutics Executive Vice President, Chief Commercial Officer Anand Varadan receives $2.3M in 2018
April 19, 2019